Intervention Protocol

Taxane-platinum combination chemotherapy versus single agent platinum for the first-line treatment of epithelial ovarian cancer

  1. Nick Johnson1,*,
  2. Tracie Miles1,
  3. Paul Cornes2,
  4. Edward Gilby3

Editorial Group: Cochrane Gynaecological Cancer Group

Published Online: 12 DEC 2012

DOI: 10.1002/14651858.CD010194


How to Cite

Johnson N, Miles T, Cornes P, Gilby E. Taxane-platinum combination chemotherapy versus single agent platinum for the first-line treatment of epithelial ovarian cancer (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD010194. DOI: 10.1002/14651858.CD010194.

Author Information

  1. 1

    Royal United Hospital NHS Trust, Gynaecological Oncology, Bath, UK

  2. 2

    University Hospitals Bristol NHS Foundation Trust, Bristol Haematology and Oncology Centre, Bristol, UK

  3. 3

    Bath Clinic, Bath, UK

*Nick Johnson, Gynaecological Oncology, Royal United Hospital NHS Trust, Combe Park, Bath, BA1 3NG, UK. nicholasjohnson@msn.com. nickjohnson@nhs.net.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 12 DEC 2012

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate the benefit and harms of adding a taxane to platinum therapy compared to platinum chemotherapy alone for the primary management of epithelial ovarian, fallopian tube or peritoneal epithelial adenocarcinoma.